Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615481 | 1.00 | MAPT (0.48) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL716533 | 1.00 | MAPT (0.48) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL2590490 | 0.95 | LMNA (0.52) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL718199 | 0.95 | LMNA (0.52) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL5221398 | 0.95 | LMNA (0.52) | MAPTLMNASLC7A5CYP1A2CYP2C9 | |
| SCHEMBL8813869 | 0.91 | P2RX7 (0.47) | MAPTLMNACYP1A2CYP2C9SLC15A1 | |
| SCHEMBL6895557 | 0.91 | ALDH1A1 (0.50) | MAPTLMNACYP1A2CYP2C9SLC15A1 | |
| SCHEMBL8813866 | 0.91 | P2RX7 (0.47) | MAPTLMNACYP1A2CYP2C9SLC15A1 | |
| SCHEMBL7302285 | 0.90 | LTA4H (0.56) | MAPTLMNALNPEPLTA4HLAP3 | |
| SCHEMBL27403149 | 0.90 | MMP1 (0.46) | MAPTLMNALTA4HLAP3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148721-A1 | DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2024-05-09 | — | — | US | disclosed |
| CN-110637007-B9 | Synthesis of tyrosine-derived diphenol monomers | 美敦力公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-110637007-B | Synthesis of tyrosine-derived diphenol monomers | 美敦力公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3634944-B1 | SYNTHESIS OF TYROSINE DERIVED DIPHENOL MONOMERS | MEDTRONIC INC (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-110015978-B | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine | 康化（上海）新药研发有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10786497-B2 | Discrete PEG constructs | EQUIP, LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200230133-A1 | Discrete PEG Constructs | EqIP, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3634944-A1 | SYNTHESIS OF TYROSINE DERIVED DIPHENOL MONOMERS | Medtronic, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-110637007-A | Synthesis of tyrosine-derived diphenol monomers | 美敦力公司 | 2019-12-31 | — | — | CN | disclosed |
| US-10442757-B2 | Synthesis of tyrosine derived diphenol monomers | MEDTRONIC, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20040224955-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-11-11 | — | — | US | disclosed |
| US-6794404-B2 | BENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-09-21 | — | — | US | disclosed |
| US-20030232816-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1301487-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-04-16 | — | — | EP | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-05-30 | — | — | US | disclosed |
| WO-2002004425-A2 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-17 | — | — | WO | disclosed |
| EP-0838471-A1 | PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1998-04-29 | — | — | EP | disclosed |
| CN-1156442-A | Dimeric DTPA derivatives and metal complexes thereof, medicaments containing said complexes, their use in diagnosis and therapy and process for preparing said complexes and medicaments | SCHERING AG (DE) | 1997-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442757-B2 | Synthesis of tyrosine derived diphenol monomers | TYR, TH, TYRO3 | MAPT 1403/4885LMNA 4273/4885SLC7A5 1220/4885 |
| US-20240148721-A1 | DISCRETE PEG CONSTRUCTS | MUC1, EGFR, LNPEP | MAPT 419/4885LMNA 1102/4885SLC7A5 1842/4885 |
| US-10786497-B2 | Discrete PEG constructs | MUC1, EGFR, LNPEP | MAPT 419/4885LMNA 1102/4885SLC7A5 1842/4885 |
| US-20030232816-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | MAPT 3559/4885LMNA 1560/4885SLC7A5 1600/4885 |
| US-20020065418-A1 | Inhibitors of hepatitis C virus replication; treatment of hepatitis C | HAVCR2, HCCS, ZC3HAV1 | MAPT 4597/4885LMNA 2204/4885SLC7A5 838/4885 |
| US-20200230133-A1 | Discrete PEG Constructs | MUC1, EGFR, LNPEP | MAPT 419/4885LMNA 1102/4885SLC7A5 1842/4885 |
| US-20040224955-A1 | Viral polymerase inhibitors | POLR2H, POLR2E, POLM | MAPT 3559/4885LMNA 1560/4885SLC7A5 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.